Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;18(9):1586-8.
doi: 10.1128/CVI.05107-11. Epub 2011 Jul 20.

Adeno-associated virus antibody profiles in newborns, children, and adolescents

Roberto Calcedo  1 , Hiroki Morizono, Lili Wang, Robert McCarter, Jianping He, David Jones, Mark L Batshaw, James M Wilson
Affiliations

Adeno-associated virus antibody profiles in newborns, children, and adolescents

Roberto Calcedo et al. Clin Vaccine Immunol. 2011 Sep.

Abstract

Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Distribution of the prevalence of neutralizing antibodies (NAbs) against adeno-associated virus (AAV) types 2 and 8 in 751 (AAV2, n = 353; AAV8, n = 398) plasma samples from subjects with ages ranging from 1 day to 18 years. Samples were considered positive if serum dilutions of ≥1:5 (A), ≥1:10 (B), ≥1:20 (C), or ≥1:40 (D) inhibited vector transduction by ≥50%.
See this image and copyright information in PMC

References

    1. Boutin S., et al. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21:704–712 - PubMed
    1. Burguete T., et al. 1999. Evidence for infection of the human embryo with adeno-associated virus in pregnancy. Hum. Reprod. 14:2396–2401 - PubMed
    1. Calcedo R., Vandenberghe L. H., Gao G., Lin J., Wilson J. M. 2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199:381–390 - PMC - PubMed
    1. Davidoff A. M., et al. 2005. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther. 11:875–888 - PubMed
    1. Friedman-Einat M., et al. 1997. Detection of adeno-associated virus type 2 sequences in the human genital tract. J. Clin. Microbiol. 35:71–78 - PMC - PubMed

Publication types

LinkOut - more resources